GLP-1 Weight-Loss Drugs Still Out-Earn Top AI Labs by 1.3x

Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are projected to generate roughly $97 billion in 2025 revenue, still about 1.3x the combined revenue of OpenAI and Anthropic, sparking discussion about how far top AI labs still trail pharma blockbusters.

2026-10-19 ~ 2026-10-19 · 2 related posts

• GLP-1 drugs still outearn all of AI: $97B vs $73B this year — matt_slotnick · 2026-10-19
• Ozempic + Mounjaro hit $71B revenue vs AI industry's $29B, with only 2% of patients reached — TansuYegen · 2026-10-19